Phase III Trials of Abiraterone Acetate in Patients With Chemotherapy-Naive and Docetaxei-Pretreated MCRPC

摘要

Also presented at ASCO 2012 was a late-breaking abstract with results of an interim analysis of the second phase III trial, COU-AA-302, which evaluated the efficacy and safety of AA in chemotherapy-naive patients with mCRPC.3 Both trials were multinational, randomized, double-blind, placebo-controlled studies in which patients were randomly assigned to AA (1,000 mg daily) with prednisone (5 mg twice daily) or placebo plus prednisone (5 mg twice daily). Prednisone is administered with AA to minimize toxicity.